Schumann C - Search Results

1

Safety and efficacy of the CD95-ligand inhibitor asunercept in transfusion-dependent patients with low and intermediate risk MDS.

Boch T, Luft T, Metzgeroth G, Mossner M, Jann JC, Nowak D, Meir F, Schumann C, Klemmer J, Brendel S, Fricke H, Kunz C, Weiß C, Hofmann WK, Nolte F. Boch T, et al. Among authors: schumann c. Leuk Res. 2018 May;68:62-69. doi: 10.1016/j.leukres.2018.03.007. Epub 2018 Mar 10. Leuk Res. 2018. PMID: 29549809 Clinical Trial.

2

Results from a 1-year, open-label, single arm, multi-center trial evaluating the efficacy and safety of oral Deferasirox in patients diagnosed with low and int-1 risk myelodysplastic syndrome (MDS) and transfusion-dependent iron overload.

Nolte F, Höchsmann B, Giagounidis A, Lübbert M, Platzbecker U, Haase D, Lück A, Gattermann N, Taupitz M, Baier M, Leismann O, Junkes A, Schumann C, Hofmann WK, Schrezenmeier H. Nolte F, et al. Among authors: schumann c. Ann Hematol. 2013 Jan;92(2):191-8. doi: 10.1007/s00277-012-1594-z. Epub 2012 Oct 17. Ann Hematol. 2013. PMID: 23073603 Clinical Trial.

3

Transcriptional down-regulation of the Wnt antagonist SFRP1 in haematopoietic cells of patients with different risk types of MDS.

Reins J, Mossner M, Neumann M, Platzbecker U, Schumann C, Thiel E, Hofmann WK. Reins J, et al. Among authors: schumann c. Leuk Res. 2010 Dec;34(12):1610-6. doi: 10.1016/j.leukres.2010.04.013. Epub 2010 May 14. Leuk Res. 2010. PMID: 20471677

4

Tolerability and efficacy of deferasirox in patients with transfusional iron overload: results from a German 2-year non-interventional study.

Nolte F, Nückel H, Schmidt B, Geer T, Rubanov O, Hebart H, Jarisch A, Albrecht S, Johr C, Schumann C, Hofmann WK. Nolte F, et al. Among authors: schumann c. J Cancer Res Clin Oncol. 2018 Aug;144(8):1531-1538. doi: 10.1007/s00432-018-2665-x. Epub 2018 May 14. J Cancer Res Clin Oncol. 2018. PMID: 29761371

5

High erythroferrone expression in CD71⁺ erythroid progenitors predicts superior survival in myelodysplastic syndromes.

Riabov V, Mossner M, Stöhr A, Jann JC, Streuer A, Schmitt N, Knaflic A, Nowak V, Weimer N, Obländer J, Palme I, Schumann C, Baldus CD, Schulze TJ, Wuchter P, Röhl H, Jawhar A, Weiss C, Boch T, Metzgeroth G, Neumann M, Hofmann WK, Nolte F, Nowak D. Riabov V, et al. Among authors: schumann c. Br J Haematol. 2021 Mar;192(5):879-891. doi: 10.1111/bjh.17314. Epub 2021 Jan 24. Br J Haematol. 2021. PMID: 33486765

6

Clinical management of gastrointestinal disturbances in patients with myelodysplastic syndromes receiving iron chelation treatment with deferasirox.

Nolte F, Angelucci E, Beris P, Macwhannell A, Selleslag D, Schumann C, Xicoy B, Almeida A, Guerci-Bresler A, Sliwa T, Muus P, Porter J, Hofmann WK. Nolte F, et al. Among authors: schumann c. Leuk Res. 2011 Sep;35(9):1131-5. doi: 10.1016/j.leukres.2011.06.013. Epub 2011 Jul 6. Leuk Res. 2011. PMID: 21737138

7

Characteristics of MDS patients seen at private practices differ significantly from those treated at university hospitals in Germany.

Nolte F, Schumann C, Klein S, Reinwald M, Hofmann WK. Nolte F, et al. Among authors: schumann c. J Cancer Res Clin Oncol. 2012 Jun;138(6):953-7. doi: 10.1007/s00432-012-1168-4. Epub 2012 Feb 23. J Cancer Res Clin Oncol. 2012. PMID: 22358300

8

Centrosome aberrations in bone marrow cells from patients with myelodysplastic syndromes correlate with chromosomal instability.

Nolte F, Giehl M, Haass W, Nowak V, Schumann C, Nowak D, Mossner M, Popp HD, Schulze TJ, Klein S, Seifarth W, Hofmann WK, Fabarius A. Nolte F, et al. Among authors: schumann c. Ann Hematol. 2013 Oct;92(10):1325-33. doi: 10.1007/s00277-013-1772-7. Epub 2013 May 5. Ann Hematol. 2013. PMID: 23645217

9

Prognostic significance of ASXL1 mutations in patients with myelodysplastic syndromes.

Thol F, Friesen I, Damm F, Yun H, Weissinger EM, Krauter J, Wagner K, Chaturvedi A, Sharma A, Wichmann M, Göhring G, Schumann C, Bug G, Ottmann O, Hofmann WK, Schlegelberger B, Heuser M, Ganser A. Thol F, et al. Among authors: schumann c. J Clin Oncol. 2011 Jun 20;29(18):2499-506. doi: 10.1200/JCO.2010.33.4938. Epub 2011 May 16. J Clin Oncol. 2011. PMID: 21576631

10

IDH1 mutations in patients with myelodysplastic syndromes are associated with an unfavorable prognosis.

Thol F, Weissinger EM, Krauter J, Wagner K, Damm F, Wichmann M, Göhring G, Schumann C, Bug G, Ottmann O, Hofmann WK, Schlegelberger B, Ganser A, Heuser M. Thol F, et al. Among authors: schumann c. Haematologica. 2010 Oct;95(10):1668-74. doi: 10.3324/haematol.2010.025494. Epub 2010 May 21. Haematologica. 2010. PMID: 20494930 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

410 results

Search Page